Evidence map›Paper›PMID 38827502›Full record

ArticleInternational journal of microbiology2024

Antimicrobial Susceptibility Testing for Colistin: Extended Application of Novel Quantitative and Morphologic Assay Using Scanning Electron Microscopy.

Omar Zmerli, Sara Bellali, Gabriel Haddad, Rim Iwaza, Akiko Hisada, Erino Matsumoto, Yusuke Ominami, Didier Raoult, Jacques Bou Khalil

Abstract read
In one paragraph

Article in International journal of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Omar ZmerliInstitut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France.ORCID https://orcid.org/0000-0002-7908-0394
Sara BellaliInstitut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France.ORCID https://orcid.org/0000-0002-7668-6294
Gabriel HaddadInstitut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France.ORCID https://orcid.org/0000-0002-6133-9185
Rim IwazaInstitut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France.
Akiko HisadaHitachi, Ltd., Research & Development Group, Tokyo, Japan.
Erino MatsumotoHitachi, Ltd., Research & Development Group, Tokyo, Japan.
Yusuke OminamiHitachi High-Tech Corporation, 882 Ichige, Hitachinaka-shi, Ibaraki-ken 312-8504, Japan.
Didier RaoultConsulting Infection Marseille, 16 Rue de Lorraine, Marseille, France.ORCID https://orcid.org/0000-0002-0633-5974
Jacques Bou KhalilInstitut Hospitalo-Universitaire Méditerranée-Infection, Marseille, France.ORCID https://orcid.org/0000-0002-4272-5208

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colistin (Polymyxin E) has reemerged in the treatment of MDR Gram-negative infections. Traditional Colistin AST methods have long turnaround times and are cumbersome for routine use. We present a SEM-AST technique enabling rapid detection of Colistin resistance through direct observation of morphological and quantitative changes in bacteria exposed to Colistin. Methods: Forty-four Gram-negative reference organisms were chosen based on their Colistin susceptibility profiles. Bacterial suspensions of ∼10 Results: We identified a significant drop in the percentage of viable organisms starting 30 minutes after exposure in susceptible strains, as compared to nonsignificant changes in resistant strains across all tested organisms. The killing effect of Colistin was best observed after 120 minutes of incubation with the antibiotic, with significant changes in morphologic features, including bacterial inflation, fusion, and lysis, observed as early as 30 minutes. Our observation matched the results of the gold standard-based broth microdilution method. Conclusions: We provide an extended application of the proof of concept for the utilization of the SEM-AST assay for Colistin for a number of clinically relevant bacterial species, providing a rapid and reliable susceptibility profile for a critical antibiotic.

Identifiers

PMID38827502
PMCPMC11144066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.